NCT01253460 - Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2011

Primary Completion Date

March 28, 2018

Study Completion Date

February 13, 2019

Conditions

Leukemia

Interventions

DRUG

Cyclophosphamide

250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.

DRUG

Rituximab

375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.

DRUG

Sapacitabine

350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston